Iris Isufi, MD
Associate Professor of Medicine (Hematology)Cards
About
Research
Publications
2025
Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Isufi I, Crombie J, Frigault M, Andreadis C, Lin Y, Mirza A, Kim S, Bernasconi D, Toron F, Krimmel T, Roy D, Pasquini M, Ahmed S. Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Transplantation And Cellular Therapy 2025, 31: s215. DOI: 10.1016/j.jtct.2025.01.329.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeDuration of responseLiso-celNonrelapse mortalityCR rateCenter for International Blood and Marrow Transplant Research (CIBMTR) registryMedian duration of responseCAR-T cell productsLarge B-cell lymphomaB-cell lymphomaClinically significant infectionsB-cell malignanciesT cell productionConsistent with clinical studiesCD19-directedExtranodal involvementLisocabtagene maraleucelNRM ratesProlonged cytopeniasR/R LBCLIndolent lymphomaData cutoffElevated LDHRadiation therapyOutcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience
Taborda C, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience. Transplantation And Cellular Therapy 2025, 31: s393-s394. DOI: 10.1016/j.jtct.2025.01.606.Peer-Reviewed Original ResearchAcute graft-versus-host diseaseReduced-intensity conditioningGraft-versus-lymphomaNon-relapse mortalityPosttransplant cyclophosphamideT-cell lymphomaAllo-SCTOverall survivalGVHD prophylaxisT cellsAssociated with improved overall survivalTacrolimus-based GVHD prophylaxisAllogeneic stem cell transplantationGraft-versus-host diseaseAggressive T-cell lymphomaT-cell lymphoma patientsHaplo-identical transplantationReduced intensity conditioningImproved overall survivalRelapse-free survivalMedian follow-upSingle-center experienceReduce treatment toxicityStem cell transplantationSingle institution experiencePatient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Vogel M, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Florendo E, Karlin L, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet Haematology 2025, 12: e45-e56. PMID: 39756844, DOI: 10.1016/s2352-3026(24)00320-x.Peer-Reviewed Original ResearchConceptsLenalidomide-refractory multiple myelomaStandard of careVisual analogue scaleMultiple myelomaGlobal health statusPatient-reported outcomesCiltacabtagene autoleucelIntention-to-treat populationLenalidomide-refractory diseaseProgression-free survivalECOG performance statusPhase 3 trialEORTC global health statusWorsening of symptomsClinically meaningful improvementsEuropean Organisation for ResearchEQ-5D-5L visual analogue scaleCilta-celEuroQol 5-Dimension 5-LevelOpen-labelImmunomodulatory drugsMedian agePerformance statusSecondary endpointsClinical efficacy
2024
Outcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients
Qureshi H, Kiwan A, Foss F, Kothari S, Huntington S, Isufi I, Seropian S, Sethi T. Outcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients. Blood 2024, 144: 6421-6421. DOI: 10.1182/blood-2024-211850.Peer-Reviewed Original ResearchAdult T-cell leukemia/lymphomaWhite blood cellsProgression free survivalWhite blood cell countOverall survivalHuman immunodeficiency virusComplete responseProgressive diseaseATLL patientsHD-MTXInstitutional cohortResponse to first line therapyAdult T-cell leukemia/lymphoma patientsMultivariate analysisMedian progression free survivalMedian time to relapseAllogeneic stem cell transplantationHuman T-cell lymphotropic virus type 1Median age of diagnosisMedian white blood cellMedian overall survivalHigh-dose methotrexateMulti-agent chemotherapyFirst line therapyMedian follow-upReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e96-e102. PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s462-s463. DOI: 10.1016/s2152-2650(24)01497-6.Peer-Reviewed Original ResearchLiso-celDuration of responseFollicular lymphomaBridging therapyBT subgroupR/R follicular lymphomaMedian follow-upHigh-risk populationSlow disease progressionFL diagnosisLisocabtagene maraleucelSecond-lineCR ratePrimary endpointSecondary endpointsInvestigator's discretionSafety profileFollow-upConsenting patientsDisease progressionSafety signalsOutpatient monitoringImprove outcomesResponse rateOutpatient settingImpact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s212. DOI: 10.1016/s2152-2650(24)00792-4.Peer-Reviewed Original ResearchP-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchP-096 Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy
Weisel K, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Karlin L. P-096 Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s97-s98. DOI: 10.1016/s2152-2650(24)01999-2.Peer-Reviewed Original ResearchAddressing platelet insecurity – A national call to action
Gehrie E, Young P, Basavaraju S, Bracey A, P. A, Culler L, Dunbar N, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey C, Kaufman R, Snyder E. Addressing platelet insecurity – A national call to action. Transfusion 2024, 64: 2001-2013. PMID: 39133194, PMCID: PMC11921857, DOI: 10.1111/trf.17987.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
HIC ID2000032539RolePrincipal InvestigatorPrimary Completion Date05/19/2029Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
HIC ID2000028478RolePrincipal InvestigatorPrimary Completion Date07/30/2023Recruiting Participants
Academic Achievements & Community Involvement
News & Links
News
- March 31, 2025
Yale’s Post ASH Review: Highlights from the 2024 American Society of Hematology Annual Meeting
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- July 30, 2024
Smilow Cancer Hospital Cellular Therapies Program
- November 08, 2023
Smilow Shares with Primary Care: Lymphadenopathy and Diagnosis